ATE520404T1 - Verfahren zur behandlung einer verletzung des zentralen nervensystems durch ausschleichende verabreichung von progesteron - Google Patents

Verfahren zur behandlung einer verletzung des zentralen nervensystems durch ausschleichende verabreichung von progesteron

Info

Publication number
ATE520404T1
ATE520404T1 AT06739662T AT06739662T ATE520404T1 AT E520404 T1 ATE520404 T1 AT E520404T1 AT 06739662 T AT06739662 T AT 06739662T AT 06739662 T AT06739662 T AT 06739662T AT E520404 T1 ATE520404 T1 AT E520404T1
Authority
AT
Austria
Prior art keywords
nervous system
central nervous
system injury
progesterone
teader
Prior art date
Application number
AT06739662T
Other languages
English (en)
Inventor
Donald Stein
Sarah Cutler
Original Assignee
Univ Emory
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Emory filed Critical Univ Emory
Application granted granted Critical
Publication of ATE520404T1 publication Critical patent/ATE520404T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
AT06739662T 2005-03-24 2006-03-24 Verfahren zur behandlung einer verletzung des zentralen nervensystems durch ausschleichende verabreichung von progesteron ATE520404T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US66472805P 2005-03-24 2005-03-24
US72966305P 2005-10-24 2005-10-24
PCT/US2006/010984 WO2006102644A2 (en) 2005-03-24 2006-03-24 Methods for the treatment of central nervous system injury via a tapered administration of progesterone

Publications (1)

Publication Number Publication Date
ATE520404T1 true ATE520404T1 (de) 2011-09-15

Family

ID=36987966

Family Applications (2)

Application Number Title Priority Date Filing Date
AT06739662T ATE520404T1 (de) 2005-03-24 2006-03-24 Verfahren zur behandlung einer verletzung des zentralen nervensystems durch ausschleichende verabreichung von progesteron
AT08167618T ATE499104T1 (de) 2005-03-24 2006-03-24 Progesterone dosierungsanweisung in der behandlung einer traumatischen verletzung des gehirns

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT08167618T ATE499104T1 (de) 2005-03-24 2006-03-24 Progesterone dosierungsanweisung in der behandlung einer traumatischen verletzung des gehirns

Country Status (16)

Country Link
US (4) US20090221544A1 (de)
EP (5) EP1871382B1 (de)
JP (5) JP5394059B2 (de)
AT (2) ATE520404T1 (de)
AU (2) AU2006226811B2 (de)
CA (2) CA2601715C (de)
CY (2) CY1111478T1 (de)
DE (1) DE602006020353D1 (de)
DK (2) DK1868614T3 (de)
ES (2) ES2428313T3 (de)
HK (3) HK1112579A1 (de)
HR (2) HRP20110198T1 (de)
PL (2) PL2030622T3 (de)
PT (2) PT2030622E (de)
RS (1) RS52471B (de)
WO (2) WO2006102596A2 (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7473687B2 (en) * 2005-03-24 2009-01-06 Emory University Methods for the treatment of a traumatic central nervous system injury
ES2428313T3 (es) 2005-03-24 2013-11-07 Emory University Métodos para el tratamiento de lesiones del sistema nervioso central mediante un protocolo de administración decreciente
EP2052724A1 (de) 2007-10-26 2009-04-29 sanofi-aventis Verwendung von Norgestimat als selektivem Hemmer der Ionenkanäle TRPC3, TRPC6 sowie TRPC6 und TRPC7
WO2009108804A2 (en) 2008-02-26 2009-09-03 Emory University Steroid analogues for neuroprotection
ES2553968T3 (es) 2008-09-18 2015-12-15 Northwestern University Moduladores del receptor NMDA y sus usos
US20110306579A1 (en) * 2009-01-30 2011-12-15 Emory University Methods of neuroprotection using neuroprotective steroids and a vitamin d
US8951968B2 (en) 2009-10-05 2015-02-10 Northwestern University Methods of treating depression and other related diseases
US20110262502A1 (en) * 2010-02-08 2011-10-27 Prairie Pharmaceuticals LLC Pulmonary delivery of 17-hydroxyprogesterone caproate (17-hpc)
US10993879B2 (en) * 2010-02-08 2021-05-04 Shenzhen Evergreen Therapeutics Co., Ltd. Pulmonary delivery of progestogen
US10987361B2 (en) 2010-02-08 2021-04-27 Shenzhen Evergreen Therapeutics Co., Ltd. Treating auto-immune and auto-inflammatory diseases
WO2011097571A2 (en) 2010-02-08 2011-08-11 Prairie Pharmaceuticals, Llc Methods for the use of progestogen as a glucocorticoid sensitizer
TW201138782A (en) 2010-04-26 2011-11-16 Besins Healthcare Lu Sarl Low-oil pharmaceutical emulsion compositions comprising progestogen
KR20190037359A (ko) * 2011-04-27 2019-04-05 노오쓰웨스턴 유니버시티 알츠하이머병, 헌팅톤병, 자폐증 또는 기타 장애의 치료 방법
WO2013043985A1 (en) 2011-09-23 2013-03-28 The Regents Of The University Of California Edible oils to enhance delivery of orally administered steroids
CN112472814A (zh) * 2012-01-23 2021-03-12 萨奇治疗股份有限公司 神经活性类固醇制剂和治疗中枢神经系统障碍的方法
US20130210785A1 (en) 2012-02-15 2013-08-15 Emory University Progesterone analogs and uses related thereto
EP2819650A1 (de) 2012-02-29 2015-01-07 B. Braun Melsungen AG Hormonhaltige emulsion mit krillphospholipiden
RU2498826C1 (ru) * 2012-05-14 2013-11-20 Федеральное государственное бюджетное учреждение науки Комплексный научно-исследовательский институт им. Х.И. Ибрагимова Российской академии наук Способ лечения больных с черепно-мозговой травмой
RU2667010C2 (ru) * 2012-08-21 2018-09-13 Сейдж Терапьютикс, Инк. Способы лечения эпилепсии или эпилептического статуса
EP4335505A3 (de) 2012-11-30 2024-06-05 The Regents of The University of California Antikonvulsive aktivität von steroiden
MX2015009772A (es) 2013-01-29 2016-05-31 Aptinyx Inc Moduladores de receptores nmda de espiro-lactama y sus usos.
CN105026401A (zh) 2013-01-29 2015-11-04 诺雷克斯股份有限公司 螺-内酰胺nmda受体调节剂及其用途
CN105229010A (zh) 2013-01-29 2016-01-06 阿普廷伊克斯股份有限公司 螺-内酰胺nmda受体调节剂及其用途
US9708335B2 (en) 2013-01-29 2017-07-18 Apytinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof
KR102280616B1 (ko) 2013-01-29 2021-07-21 앱티닉스 인크. 스피로-락탐 nmda 수용체 조절인자 및 그의 용도
US9802978B2 (en) 2013-08-12 2017-10-31 Emory University Progesterone phosphate analogs and uses related thereto
US10231979B2 (en) * 2015-08-07 2019-03-19 Indiana University Research And Technology Corporation Modulation of inflammation using progesterone metabolites
CN109414444A (zh) 2016-03-08 2019-03-01 萨奇治疗股份有限公司 神经活性类固醇、其组合物及用途
WO2017201285A1 (en) 2016-05-19 2017-11-23 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
CA3024606C (en) 2016-05-19 2019-09-03 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
AU2017305240B2 (en) 2016-08-01 2021-12-09 Aptinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof
SG11201900558RA (en) 2016-08-01 2019-02-27 Aptinyx Inc Spiro-lactam nmda receptor modulators and uses thereof
SG10202101055VA (en) 2016-08-01 2021-03-30 Aptinyx Inc Spiro-lactam nmda receptor modulators and uses thereof
CN109661398B (zh) 2016-08-01 2022-07-05 阿普廷伊克斯股份有限公司 螺-内酰胺和二-螺-内酰胺nmda受体调节剂及其用途
WO2018026798A1 (en) 2016-08-01 2018-02-08 Aptinyx Inc. Spiro-lactam nmda modulators and methods of using same
MX2020008107A (es) 2018-01-31 2020-09-25 Aptinyx Inc Moduladores del receptor nmda espiro-lactama y usos de los mismos.
EP3935581A4 (de) 2019-03-04 2022-11-30 Iocurrents, Inc. Datenkompression und -kommunikation mit maschinenlernung
US12012413B2 (en) 2019-11-11 2024-06-18 Tenacia Biotechnology (Hong Kong) Co., Limited Methods of treating painful diabetic peripheral neuropathy
WO2023102149A1 (en) * 2021-12-02 2023-06-08 MarvelBiome, Inc. Methods and uses of microbiome compositions, components, or metabolites for treating vagus nerve associated diseases, disorders, and conditions
WO2024059056A1 (en) * 2022-09-12 2024-03-21 Emory University Methods of managing traumatic brain injury

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5217085A (en) 1975-07-30 1977-02-08 Ono Pharmaceut Co Ltd Method of quantitative determination of free fatty acids in serum usin g fatty acid activating enzymes
US4404366A (en) * 1980-05-06 1983-09-13 Miles Laboratories, Inc. Beta-galactosyl-umbelliferone-labeled hapten conjugates
US4369250A (en) 1981-07-31 1983-01-18 Sherwood Medical Industries Inc. Fatty acid determination
USRE35517E (en) * 1987-08-25 1997-05-20 University Of Southern California Method, compositions, and compounds for modulating brain excitability
EP0382790A4 (en) 1987-08-25 1991-03-27 Kelvin W. Gee Compositions and methods for alleviating stress, anxiety and seizure activity
US5232917A (en) * 1987-08-25 1993-08-03 University Of Southern California Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series
US5120723A (en) * 1987-08-25 1992-06-09 University Of Southern California Method, compositions, and compounds for modulating brain excitability
US5512429A (en) 1989-09-19 1996-04-30 British Technology Group Limited Assay for enzyme activity
GB9105707D0 (en) 1991-03-18 1991-05-01 Wilton David C Assay
US5114388A (en) * 1991-07-26 1992-05-19 True Fitness Technology, Inc. Stair simulator exerciser with adjustable incline
US5212167A (en) * 1991-09-12 1993-05-18 Trustees Of Boston University Modulation of receptor-mediated ion transport
US5206415A (en) * 1991-12-20 1993-04-27 Washington University Tricyclic steroid analogs
ATE275957T1 (de) * 1993-01-19 2004-10-15 Endorech Inc Therapeutische verwendungen und verabreichungsysteme von dehydroepiandrosteron
US5776923A (en) * 1993-01-19 1998-07-07 Endorecherche, Inc. Method of treating or preventing osteoporosis by adminstering dehydropiandrosterone
DE4311870C2 (de) 1993-04-10 1998-07-30 Altramed Holdings Ltd Verwendung eines Anti-Östrigens zur Therapie und Prophylaxe von Demenz-Erkrankungen
AU7569194A (en) * 1993-08-20 1995-03-21 Meyer B. Jackson Method for regulating neuropeptide hormone secretion
US5763431A (en) * 1993-08-20 1998-06-09 Jackson; Meyer B. Method for regulating neuropeptide hormone secretion
US5939545A (en) * 1994-02-14 1999-08-17 Cocensys, Inc. Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series
US5633011A (en) * 1994-08-04 1997-05-27 Alza Corporation Progesterone replacement therapy
FR2727117A1 (fr) * 1994-11-18 1996-05-24 Geffard Michel Utilisation de conjugues de la polylysine pour la preparation de medicaments utiles dans le traitement des maladies neurodegeneratives et des affections degeneratives a caractere autoimmun
US5767117A (en) * 1994-11-18 1998-06-16 The General Hospital Corporation Method for treating vascular headaches
US5741899A (en) * 1995-02-02 1998-04-21 Cell Genesys, Inc. Chimeric receptors comprising janus kinase for regulating cellular pro liferation
GEP20012530B (en) * 1995-06-06 2001-09-25 Cocensys Inc Neuroactive Steroids of the Androstane and Pregnane Series
AU706541B2 (en) * 1995-06-09 1999-06-17 Euro-Celtique S.A. Formulations and methods for providing prolonged local anesthesia
US5888996A (en) * 1995-07-26 1999-03-30 Trustees Of Boston University Inhibition of NMDA receptor activity and modulation of glutamate-mediated synaptic activity
WO1997043989A1 (en) 1996-05-22 1997-11-27 Diversified Pharmaceuticals, Inc. Compositions, methods and devices for the transdermal delivery of drugs
US5763492A (en) * 1996-10-01 1998-06-09 Duguesne University Of The Holy Ghost Methods for effecting memory enhancement mediated by non-steroidal sulfatase inhibitors
DE69809223T2 (de) 1997-05-02 2003-07-24 Wyeth Corp 5-alpha-pregnan-3-beta-ol-20-one 3-sulfate für di behandlung von tumoren und zns krankheiten
US6245757B1 (en) * 1997-10-03 2001-06-12 Research Corporation Technologies, Inc. Use of progestins to treat ischemic event
US6174547B1 (en) * 1999-07-14 2001-01-16 Alza Corporation Dosage form comprising liquid formulation
US6268223B1 (en) 1999-08-27 2001-07-31 Viatech Imagin, Llc Assay for detecting damage to the central nervous system
US20020072509A1 (en) * 2000-10-11 2002-06-13 Stein Donald Gerald Methods for the treatment of a traumatic central nervous system injury
US7473687B2 (en) * 2005-03-24 2009-01-06 Emory University Methods for the treatment of a traumatic central nervous system injury
ES2428313T3 (es) * 2005-03-24 2013-11-07 Emory University Métodos para el tratamiento de lesiones del sistema nervioso central mediante un protocolo de administración decreciente

Also Published As

Publication number Publication date
CY1111478T1 (el) 2015-08-05
ES2392454T3 (es) 2012-12-10
JP2008534512A (ja) 2008-08-28
HRP20110198T1 (hr) 2011-04-30
CA2602950A1 (en) 2006-09-28
US20090221544A1 (en) 2009-09-03
CY1113253T1 (el) 2016-04-13
WO2006102596A3 (en) 2007-01-18
US20120245133A1 (en) 2012-09-27
EP2431042B1 (de) 2013-06-26
PL2030622T3 (pl) 2011-07-29
US20090325920A1 (en) 2009-12-31
JP2014055183A (ja) 2014-03-27
PT2030622E (pt) 2011-06-02
JP2013234191A (ja) 2013-11-21
CA2601715C (en) 2012-10-16
AU2006226774B2 (en) 2010-12-02
EP2494976A1 (de) 2012-09-05
PT1868614E (pt) 2012-11-23
CA2601715A1 (en) 2006-09-28
WO2006102644A2 (en) 2006-09-28
WO2006102644A3 (en) 2007-03-01
US20120289491A1 (en) 2012-11-15
EP1871382A2 (de) 2008-01-02
JP5394059B2 (ja) 2014-01-22
EP2030622A1 (de) 2009-03-04
HK1128242A1 (en) 2009-10-23
WO2006102644A9 (en) 2006-11-23
JP5295755B2 (ja) 2013-09-18
JP2011225629A (ja) 2011-11-10
PL1868614T3 (pl) 2013-01-31
EP2431042A1 (de) 2012-03-21
WO2006102596A2 (en) 2006-09-28
JP5496407B2 (ja) 2014-05-21
CA2602950C (en) 2012-10-30
RS52471B (en) 2013-02-28
AU2006226774A1 (en) 2006-09-28
EP1868614A2 (de) 2007-12-26
US8614203B2 (en) 2013-12-24
AU2006226811A1 (en) 2006-09-28
EP2030622B1 (de) 2011-02-23
HK1112581A1 (en) 2008-09-12
HK1112579A1 (en) 2008-09-12
DE602006020353D1 (de) 2011-04-07
ES2428313T3 (es) 2013-11-07
EP1871382B1 (de) 2011-08-17
DK2030622T3 (da) 2011-05-02
HRP20120688T1 (hr) 2012-09-30
AU2006226811B2 (en) 2010-11-25
ATE499104T1 (de) 2011-03-15
EP1868614B1 (de) 2012-08-08
JP2008534515A (ja) 2008-08-28
DK1868614T3 (da) 2012-11-12

Similar Documents

Publication Publication Date Title
ATE520404T1 (de) Verfahren zur behandlung einer verletzung des zentralen nervensystems durch ausschleichende verabreichung von progesteron
WO2008039898A3 (en) Methods for the treatment of a traumatic central nervous system injury
ATE480255T1 (de) Zusammensetzungen und verfahren zur kontrolle, prävention und behandlung von essstörungen
WO2008083204A3 (en) Modulation of neurogenesis by melatoninergic ligands
WO2007143098A8 (en) Hepatocyte growth factor (hgf) binding proteins
WO2007143090A3 (en) Hepatocyte growth factor (hgf) binding proteins
NO20054988D0 (no) Preparater og metoder for behandling av cancer
WO2007047978A3 (en) Modulation of neurogenesis by pde inhibition
WO2008097861A3 (en) MODULATION OF NEUROGENESIS WITH BIGUANIDES AND GSK3-ß AGENTS
BRPI0911482A2 (pt) Uso de epotilona d no tratamento de doenças associadas a tau incluindo doenças de alzheimer
WO2017190044A8 (en) Methods for detecting and treating pain using brain activity
EP2253305A3 (de) Hautbehandlung zur Porenverfeinerung
WO2011091154A3 (en) Use of human erythrocytes for prevention and treatment of cancer dissemination and growth
WO2007089733A3 (en) Regimens for treatment of conditions related to estrogen deficiency
DE60330501D1 (de) Verfahren zur behandlung von verletzungen des nervensystems in verbindung mit einer blutung
BRPI0514815A (pt) método para tratar um distúrbio de pele hiperproliferativa, e, composição farmacêutica
MX2019001337A (es) Métodos para tratar y prevenir efectos secundarios por tratamiento de cáncer.
WO2014201084A3 (en) Piroxicam transdermal composition to treat plantar fasciitis
ATE510530T1 (de) Verfahren zur verhinderung und/oder behandlung von altersflecken
MX2015013137A (es) Compuestos novedosos de modulación del control de la respiración, y sus métodos de uso.
WO2014012025A3 (en) Igf-1 proteins and therapeutic uses thereof
BR112014029308A2 (pt) um método de melhorar a função hepática
CL2019000236A1 (es) Composición y uso de un péptido.
RU2014114121A (ru) Средство и способ местного лечения папуло-пустулезной формы розацеа
WO2015051279A3 (en) Cxcr4 up- and down-regulation for treatment of diseases or disorders

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties